These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 26879463)

  • 1. Extending (Q)SARs to incorporate proprietary knowledge for regulatory purposes: A case study using aromatic amine mutagenicity.
    Ahlberg E; Amberg A; Beilke LD; Bower D; Cross KP; Custer L; Ford KA; Van Gompel J; Harvey J; Honma M; Jolly R; Joossens E; Kemper RA; Kenyon M; Kruhlak N; Kuhnke L; Leavitt P; Naven R; Neilan C; Quigley DP; Shuey D; Spirkl HP; Stavitskaya L; Teasdale A; White A; Wichard J; Zwickl C; Myatt GJ
    Regul Toxicol Pharmacol; 2016 Jun; 77():1-12. PubMed ID: 26879463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Principles and procedures for implementation of ICH M7 recommended (Q)SAR analyses.
    Amberg A; Beilke L; Bercu J; Bower D; Brigo A; Cross KP; Custer L; Dobo K; Dowdy E; Ford KA; Glowienke S; Van Gompel J; Harvey J; Hasselgren C; Honma M; Jolly R; Kemper R; Kenyon M; Kruhlak N; Leavitt P; Miller S; Muster W; Nicolette J; Plaper A; Powley M; Quigley DP; Reddy MV; Spirkl HP; Stavitskaya L; Teasdale A; Weiner S; Welch DS; White A; Wichard J; Myatt GJ
    Regul Toxicol Pharmacol; 2016 Jun; 77():13-24. PubMed ID: 26877192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extending (Q)SARs to incorporate proprietary knowledge for regulatory purposes: is aromatic N-oxide a structural alert for predicting DNA-reactive mutagenicity?
    Amberg A; Anger LT; Bercu J; Bower D; Cross KP; Custer L; Harvey JS; Hasselgren C; Honma M; Johnson C; Jolly R; Kenyon MO; Kruhlak NL; Leavitt P; Quigley DP; Miller S; Snodin D; Stavitskaya L; Teasdale A; Trejo-Martin A; White AT; Wichard J; Myatt GJ
    Mutagenesis; 2019 Mar; 34(1):67-82. PubMed ID: 30189015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transitioning to composite bacterial mutagenicity models in ICH M7 (Q)SAR analyses.
    Landry C; Kim MT; Kruhlak NL; Cross KP; Saiakhov R; Chakravarti S; Stavitskaya L
    Regul Toxicol Pharmacol; 2019 Dec; 109():104488. PubMed ID: 31586682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A knowledge-based expert rule system for predicting mutagenicity (Ames test) of aromatic amines and azo compounds.
    Gadaleta D; Manganelli S; Manganaro A; Porta N; Benfenati E
    Toxicology; 2016 Aug; 370():20-30. PubMed ID: 27644887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of in silico systems and expert knowledge for structure-based assessment of potentially mutagenic impurities.
    Sutter A; Amberg A; Boyer S; Brigo A; Contrera JF; Custer LL; Dobo KL; Gervais V; Glowienke S; van Gompel J; Greene N; Muster W; Nicolette J; Reddy MV; Thybaud V; Vock E; White AT; Müller L
    Regul Toxicol Pharmacol; 2013 Oct; 67(1):39-52. PubMed ID: 23669331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carbamates and ICH M7 classification: Making use of expert knowledge.
    Hemingway R; Fowkes A; Williams RV
    Regul Toxicol Pharmacol; 2017 Jun; 86():392-401. PubMed ID: 28385577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. (Q)SAR assessments of potentially mutagenic impurities: a regulatory perspective on the utility of expert knowledge and data submission.
    Powley MW
    Regul Toxicol Pharmacol; 2015 Mar; 71(2):295-300. PubMed ID: 25545315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the impact of expert knowledge on ICH M7 (Q)SAR predictions. Is expert review still needed?
    Jayasekara PS; Skanchy SK; Kim MT; Kumaran G; Mugabe BE; Woodard LE; Yang J; Zych AJ; Kruhlak NL
    Regul Toxicol Pharmacol; 2021 Oct; 125():105006. PubMed ID: 34273441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanistic Reactivity Descriptors for the Prediction of Ames Mutagenicity of Primary Aromatic Amines.
    Kuhnke L; Ter Laak A; Göller AH
    J Chem Inf Model; 2019 Feb; 59(2):668-672. PubMed ID: 30694664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutagenicity assessment strategy for pharmaceutical intermediates to aid limit setting for occupational exposure.
    Araya S; Lovsin-Barle E; Glowienke S
    Regul Toxicol Pharmacol; 2015 Nov; 73(2):515-20. PubMed ID: 26454093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Principles and procedures for handling out-of-domain and indeterminate results as part of ICH M7 recommended (Q)SAR analyses.
    Amberg A; Andaya RV; Anger LT; Barber C; Beilke L; Bercu J; Bower D; Brigo A; Cammerer Z; Cross KP; Custer L; Dobo K; Gerets H; Gervais V; Glowienke S; Gomez S; Van Gompel J; Harvey J; Hasselgren C; Honma M; Johnson C; Jolly R; Kemper R; Kenyon M; Kruhlak N; Leavitt P; Miller S; Muster W; Naven R; Nicolette J; Parenty A; Powley M; Quigley DP; Reddy MV; Sasaki JC; Stavitskaya L; Teasdale A; Trejo-Martin A; Weiner S; Welch DS; White A; Wichard J; Woolley D; Myatt GJ
    Regul Toxicol Pharmacol; 2019 Mar; 102():53-64. PubMed ID: 30562600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. It's difficult, but important, to make negative predictions.
    Williams RV; Amberg A; Brigo A; Coquin L; Giddings A; Glowienke S; Greene N; Jolly R; Kemper R; O'Leary-Steele C; Parenty A; Spirkl HP; Stalford SA; Weiner SK; Wichard J
    Regul Toxicol Pharmacol; 2016 Apr; 76():79-86. PubMed ID: 26785392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple Instance Learning Improves Ames Mutagenicity Prediction for Problematic Molecular Species.
    Feeney SV; Lui R; Guan D; Matthews S
    Chem Res Toxicol; 2023 Aug; 36(8):1227-1237. PubMed ID: 37477941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Establishing best practise in the application of expert review of mutagenicity under ICH M7.
    Barber C; Amberg A; Custer L; Dobo KL; Glowienke S; Van Gompel J; Gutsell S; Harvey J; Honma M; Kenyon MO; Kruhlak N; Muster W; Stavitskaya L; Teasdale A; Vessey J; Wichard J
    Regul Toxicol Pharmacol; 2015 Oct; 73(1):367-77. PubMed ID: 26248005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of Toxtree and SciQSAR in silico predictive software using a publicly available benchmark mutagenicity database and their applicability for the qualification of impurities in pharmaceuticals.
    Contrera JF
    Regul Toxicol Pharmacol; 2013 Nov; 67(2):285-93. PubMed ID: 23969001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of In Silico Methods for Regulatory Toxicological Assessment of Pharmaceutical Impurities.
    Kovarich S; Cappelli CI
    Methods Mol Biol; 2022; 2425():537-560. PubMed ID: 35188646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the OECD QSAR Application Toolbox and Toxtree for estimating the mutagenicity of chemicals. Part 1. Aromatic amines.
    Devillers J; Mombelli E
    SAR QSAR Environ Res; 2010 Oct; 21(7-8):753-69. PubMed ID: 21120760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Construction and application of (Q)SAR models to predict chemical-induced in vitro chromosome aberrations.
    Hsu CW; Hewes KP; Stavitskaya L; Kruhlak NL
    Regul Toxicol Pharmacol; 2018 Nov; 99():274-288. PubMed ID: 30278198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A practice of expert review by read-across using QSAR Toolbox.
    Fukuchi J; Kitazawa A; Hirabayashi K; Honma M
    Mutagenesis; 2019 Mar; 34(1):49-54. PubMed ID: 30690463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.